RESEARCH MONOGRAPH · KDC-MN-1317
Benzocaine
Benzocaine is the simplest ester local anesthetic, structurally just ethyl 4-aminobenzoate without the diethylamino-ethanol group of procaine. The simpler structure makes it lipophilic and poorly water-soluble, useful only for topical mucous membrane anesthesia. You know it as the active ingredient in Cepacol throat lozenges, Anbesol and Orajel oral gels, hemorrhoidal preparations, and topical ENT and bronchoscopy sprays. Onset is rapid (15 to 60 seconds on mucous membranes); duration is 5 to 15 minutes. The main safety concern is dose-dependent methemoglobinemia, more pronounced than with prilocaine, that has driven FDA boxed warnings against benzocaine spray and gel use in infants. The mechanism is hepatic conversion to nitroso and N-hydroxy metabolites that oxidize hemoglobin. The FDA advised against benzocaine teething gels in infants under two years in 2018. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Ester local anesthetic (topical only)
The simplest ester local anesthetic, used as a topical mucous membrane anesthetic and the principal ingredient in over-the-counter sore-throat lozenges.
Abstract
Benzocaine (ethyl 4-aminobenzoate; CAS 94-09-7; molecular formula C9H11NO2; molecular weight 165.19) is an ester-class local anesthetic, structurally the simplest member of the para-aminobenzoate family (the primary aminobenzoate ester directly esterified to ethanol, lacking the diethylamino-ethanol group of procaine). The simpler structure produces a lipophilic, water-poorly-soluble compound suitable only for topical mucous membrane anesthesia; the absence of the tertiary amine restricts utility for infiltration and regional anesthesia. Benzocaine is the principal active ingredient in over-the-counter throat lozenges (Cepacol), oral analgesic gels (Anbesol, Orajel), topical preparations for hemorrhoidal and minor wound use, and topical ENT and bronchoscopy preparation. Mechanism is voltage-gated sodium channel block in surface nerve fibers contacted topically. Onset is rapid (15 to 60 seconds on mucous membranes); duration is 5 to 15 minutes. The principal safety concern is dose-dependent methemoglobinemia, more pronounced than with prilocaine, that has driven FDA boxed warnings against benzocaine spray and gel use in infants and limited topical exposure in children and adults. The mechanism is hepatic conversion of benzocaine to nitroso and N-hydroxy metabolites that oxidize hemoglobin iron to the ferric state. Clinical methemoglobinemia is reported with topical mucosal application of as little as 250 mg in vulnerable individuals; the risk is amplified in G6PD deficiency, infancy (low NADH-methemoglobin reductase activity), and concurrent oxidant drug exposure. Methylene blue is the rescue therapy. The FDA advised in 2018 against benzocaine teething gels in infants under 2 years.
Mechanism of action
Voltage-gated sodium channel block. Topical only. Methemoglobinemia from hepatic generation of nitroso and N-hydroxy metabolites.
Reported research dose ranges
Reported research dose ranges vary across the published literature.
References
- Vallurupalli S, Manchanda S. Benzocaine-induced methemoglobinemia. Chest 2011.
- FDA Drug Safety Communication: Methemoglobinemia warning. May 2018.
- Guay J. Methemoglobinemia related to local anesthetics: 242 episodes. Anesth Analg 2009.
Read the full monograph
Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.